Sinclair Pharma Bullish About Profitability By Year-End
Executive Summary
Encouraged by its solid sales performance in the first half of this year, UK aesthetics company Sinclair Pharma is optimistic it can close out 2017 with a small profit. The firm's H1 revenues were boosted by continued growth in key markets, leading to a 16% top-line growth.
You may also be interested in...
US Sales Of Sinclair Pharma's Silhouette InstaLift-Off
Aesthetics company Sinclair Pharma has reported headline growth of 51% in 2016 due to strong unexpected interest for its Silhouette Instalift product.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.